bexobrutideg

Bexobrutideg is an investigational, orally bioavailable, brain-penetrant small molecule degrader of Bruton’s tyrosine kinase (BTK). It represents a new class of targeted protein degraders that catalytically induce ubiquitination and proteasomal degradation of BTK, thereby eliminating both wild-type and mutant forms of the protein. This mechanism is distinct from traditional BTK inhibitors as it removes the entire target protein rather than simply inhibiting its activity. Bexobrutideg has demonstrated potent degradation of BTK in preclinical models and shows central nervous system (CNS) penetration with measurable concentrations in cerebrospinal fluid. It is currently being evaluated in phase 1 clinical trials for relapsed or refractory B-cell malignancies—including Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, and small lymphocytic lymphoma—and has shown promising safety and efficacy data with high response rates even in patients who have failed prior BTK inhibitor therapies. The drug also holds potential for treating inflammatory diseases[1][2][3][4][5][6][7][8][9][10].

Other names

Bexobrutideg